IRCCS Center for Tropical Diseases, Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy.
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006917. doi: 10.1371/journal.pntd.0006917. eCollection 2018 Nov.
Loa loa infection is endemic in limited areas of West-Central Africa. Loiasis has been associated with excess mortality, but clinical studies on its treatment are scant, particularly outside endemic areas, due to the rarity of cases diagnosed.
METHODOLOGY/PRINCIPAL FINDINGS: With this retrospective TropNet (European Network for Tropical Medicine and Travel Health) study, we aimed at outlining the treatment schedules followed by different reference centers for tropical medicine across Europe. We gathered information about 238 cases of loiasis, 165 of which had follow up data. The regimens followed by the different centers were heterogeneous. The drugs most frequently administered were: diethylcarbamazine alone (74/165, 45.1%), ivermectin alone (41/165, 25%), albendazole + ivermectin (21/164, 11.6%), ivermectin + diethylcarbamazine (16/165, 9.7%).
CONCLUSIONS/SIGNIFICANCE: The management of loiasis substantially differs across specialized travel clinics in Europe. These discrepancies could be due to different local protocols as well as to (un)availability of the drugs. An harmonization of clinical protocols for the treatment of loiasis would be suggested across reference centers for tropical medicine in Europe.
旋盘丝虫病流行于中非西部的一些有限地区。罗阿丝虫病与超额死亡率相关，但由于诊断出的病例罕见，因此针对其治疗的临床研究很少，尤其是在流行地区之外。
方法/主要发现：本回顾性 TropNet（热带医学和旅行健康欧洲网络）研究旨在概述欧洲不同热带医学参考中心采用的治疗方案。我们收集了 238 例旋盘丝虫病病例的信息，其中 165 例有随访数据。不同中心采用的方案存在差异。最常使用的药物有：乙胺嗪（74/165，45.1%）、伊维菌素（41/165，25%）、阿苯达唑+伊维菌素（21/164，11.6%）、伊维菌素+乙胺嗪（16/165，9.7%）。
结论/意义：欧洲专门的旅行诊所对旋盘丝虫病的治疗存在显著差异。这些差异可能是由于不同的本地方案以及药物的（可用性）差异所致。建议欧洲热带医学参考中心之间协调治疗旋盘丝虫病的临床方案。
